In the first article of a 2-part series, Douglas Sborov, MD, discusses how the efficacy results of the IKEMA trial not only show isatuximab, carfilzomib, and dexamethasone as a viable treatment option for patients with multiple myeloma, but as further proof triplet therapy is superior to doublet therapy in this patient population.
During a Targeted Oncology™ Case-Based Roundtable™ event, Balazs Halmos, MD, discussed with participants how they would approach the case of a patient with T3N0 lung adenocarcinoma of stage IIB. This is the first of 2 articles based on this event.
In the second article of a 2-part series, Pankit Vachhani, MD, highlights the impact ruxolitinib has had, and continues, to have in treatment for patients with myelofibrosis and how physicians should manage this treatment for their patients.
During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.
In the second article of a 2-part series, Hayder Saeed, MD, discusses the long-term use of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma and how the combination therapy compares in the real-world setting.
During an in-person Targeted Oncology™ Clinical Case Forum event in New Jersey, Tiffany Traina, MD, discussed the role of antibody-drug conjugates in advanced breast cancer.
These FDA approvals display a relentless pursuit of innovation in oncology, empowering oncologists with increasingly sophisticated treatment to help navigate and manage cancer’s complexities.
During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, examined the significance of the 44-month follow-up of the CheckMate 9ER trial of patients with metastatic renal cell carcinoma.
In the second article of a 2-part series, Sumit Madan, MD, talked about the manageable toxicity profile with the triplet therapy selinexor (Xpovio), bortezomib, and dexamethasone and how dose reductions led to tolerable outcomes in patients with relapsed/refractory multiple myeloma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed issues related to dosing and management of patients receiving ruxolitinib for myelofibrosis.
During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed approaches to starting JAK inhibitor therapy for a patient with myelofibrosis and when to refer for stem cell transplant. This is the first of 2 articles based on this event.
Ruta D. Rao, MD, and Virginia G. Kaklamani, MD, discuss with participants the case of a patient with breast cancer who has received multiple lines of therapy and what the next steps are for her treatment.
During a Targeted Oncology™ Case-Based Roundtable™ event, Lisa Barroilhet, MD, MS, discussed recent trials that are relevant to a patient with recurrent endometrial cancer who relapsed less than a year after a complete response to doublet chemotherapy.
The FDA has granted approval to the combination of enfortumab vedotin-ejfv and pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer.
At a live virtual event Richard Kim, MD, discussed treating patients with hepatocellular carcinoma and how the treatment approach to this disease has changed.
During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the IFM2009, DETERMINATION, and FORTE trials in patients with newly diagnosed multiple myeloma. This is the first of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew A. Powell, MD, discussed management of adverse events with the combination of lenvatinib plus pembrolizumab in patients with endometrial cancer.
In separate live events, Yasser Mohamed Ali Ged, MBBS, and Deepak Kilari, MD, discussed the best treatment options for patients with advanced renal cell carcinoma and what role tyrosine kinase inhibitors play for these patients.
In the second article of a 2-part series, Hope S. Rugo, MD, FASCO, leads a conversation on the results of the EMERLAD study that showed elacestrant’s longer survival outcomes against standard of care endocrine therapy for patients with HR+, HER2- metastatic breast cancer.
During a Targeted Oncology™ Clinical Case Forum event in partnership with the Empire State Hematology & Oncology Society, Joshua Richter, MD, discussed the GRIFFIN trial and issues in treating newly diagnosed multiple myeloma including minimal residual disease, consolidation, maintenance, and transplant.
During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan L. Kaufman, MD, and participants discussed their impressions of the efficacy and safety of the MonumenTAL-1 trial of talquetamab in patients with heavily pretreated relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.
In the second article of a 2-part series, Joshua Richter, MD, discusses how the isatuximab, carfilzomib, and dexamethasone regimen fits into the landscape of treatment for patients with early relapsed multiple myeloma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Cyrus M. Khan, MD, and participants discussed the case of a patient with diffuse large B-cell lymphoma who progressed after complete remission on standard-of-care frontline therapy, then had stable disease after receiving polatuzumab vedotin, bendamustine, and rituximab.
During a Targeted Oncology™ Case-Based Roundtable™ event, Herbert A. Eradat, MD, reviewed data supporting the use of zanubrutinib and acalabrutinib in treatment of relapsed/refractory chronic lymphocytic leukemia.
In the second article of a 2-part series, Herbert A. Eradat, MD, discusses further considerations with adding polatuzumab vedotin in combination chemotherapy in certain subgroups of patients with diffuse large B-cell lymphoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Saulius K. Girnius, MD, and participants discussed use of combination therapies including daratumumab as frontline therapy for patients with transplant-eligible multiple myeloma.
At a live virtual event, Deborah J. Wong, MD, PhD, gave her thoughts on the use of hedgehog inhibitors compared with immunotherapy in patients with infiltrative basal cell carcinoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Mancini, PharmD, BCOP, FHOPA, discussed the various approved bispecific T-cell engagers and gave guidance for healthcare professionals, patients, and caregivers related to adverse event management. This is the second of 2 articles based on this event.
In the second article of a 2-part series, Martin F. Dietrich, MD, PhD, discusses the results of the phase 1 CHRYSALIS study of amivantamab for patients with EGFR exon 20 insertion-mutated NSCLC.